Skip to Content

Tinzaparin Pregnancy and Breastfeeding Warnings

Tinzaparin is also known as: Innohep

Tinzaparin Pregnancy Warnings

Tinzaparin has been assigned to pregnancy category B by the FDA. Animal studies have not revealed evidence of teratogenicity. Cases of teratogenic effects have been reported in the literature involving infants of women who received tinzaparin during pregnancy; however, the manufacturer states that tinzaparin does not cross the placenta (based on human and animal data) and shows no evidence of teratogenic effects or fetotoxicity. There are no controlled data in human pregnancy. Tinzaparin does not appear to cross the placenta. Tinzaparin is only recommended for use during pregnancy when benefit outweighs risk.

One case each of cleft palate, optic nerve hypoplasia, and trisomy 21 syndrome have been reported in infants whose mothers received tinzaparin therapy during pregnancy. There have been four reports of fetal death/miscarriage in pregnant women who received tinzaparin. This also included pregnant women with a history of spontaneous abortion and/or high risk. Six percent of pregnancies were complicated by fetal distress. Side effects including congenital anomaly, fetal death, and fetal distress (all greater than 1.5%) have been reported. Other side effects including neonatal hypotonia have been reported in ongoing or completed clinical trials or from post marketing experience. In a study involving pregnant women (n=54) receiving tinzaparin for the treatment of venous thromboembolism or for thromboprophylaxis, doses of 50 to 175 anti-Xa units/kg once daily subcutaneously were well tolerated and no neonatal adverse events relating to tinzaparin were reported.

See references

Tinzaparin Breastfeeding Warnings

Very low levels of tinzaparin have been reported in the breast milk of lactating animals.

There are no data on the excretion of tinzaparin into human milk. The manufacturer recommends that caution be used when administering tinzaparin to nursing women.

See references

References for pregnancy information

  1. Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J "Tinzaparin sodium for thrombosis treatment and prevention during pregnancy." Am J Obstet Gynecol 190 (2004): 495-501
  2. Cheer SM, Dunn CJ, Foster R "Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease." Drugs 64 (2004): 1479-1502
  3. "Product Information. Innohep (tinzaparin)" DuPont Pharmaceuticals, Wilmington, DE.

References for breastfeeding information

  1. "Product Information. Innohep (tinzaparin)" DuPont Pharmaceuticals, Wilmington, DE.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.